| Symbol | SLN |
|---|---|
| Name | SILENCE THERAPEUTICS PLC |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 12 HAMMERSMITH GROVE, LONDON, None W6 7AP |
| Telephone | 44-0-20-3457 6900 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001479615 |
| Description | None |
New Form SCHEDULE 13D/A - Silence Therapeutics plc <b>Filed:</b> 2026-07-08 <b>AccNo:</b> 0001104659-26-081559 <b>Size:</b> 23 KB
Read moreGriffiths Richard Ian 🟢 acquired 4.6M shares (6 derivative) of Silence Therapeutics plc (SLN) at $10.76 ($49.1M) Transaction Date: Jun 29, 2026 | Filing ID: 080997
Read more(10% Negative) SILENCE THERAPEUTICS PLC (SLN) Announces Delay in upon Trials for connection wit Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read more(85% Positive) SILENCE THERAPEUTICS PLC (SLN) Provides Update on reductions for phlebotomy use as previously reported
Read moreSilence Therapeutics - Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
Read moreSilence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
Read moreNew Form EFFECT - Silence Therapeutics plc <b>Filed:</b> 2026-05-27 <b>AccNo:</b> 9999999995-26-001774 <b>Size:</b> 1 KB
Read moreNew Form 424B5 - Silence Therapeutics plc <b>Filed:</b> 2026-05-27 <b>AccNo:</b> 0001193125-26-242060 <b>Size:</b> 246 KB
Read moreSilence Therapeutics - Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
Read moreSilence Therapeutics to Participate in Jefferies Global Healthcare Conference
Read more